Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine ...

This latest price level reflects a significant downturn for the company, with the stock experiencing a precipitous 1-year change, plummeting by -77.17%. Investors are closely monitoring MRSN as it ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock ... Shares @ Avg Price of $3.25/Share ...

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Mersana Therapeutics (MRSN – Research ... a Buy rating on the stock with a $8.00 price target.

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report ... They issued a “buy” rating and a $5.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a ...